ATLASSpero Therapeutics (SPRO) earnings date: Nov 12, 2026
Spero Therapeutics (SPRO) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026, after the close. Analysts expect EPS of -$0.14.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on SPRO
| Last price | $1.06 (-4.5%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.9% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Spero Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Spero Therapeutics reports on Nov 12, 2026. One email the day before, with ATLAS’s read on Spero Therapeutics. You can switch it off at any time.
Alert me before SPRO reportsFree to start. Creating an account takes under a minute.
SPRO earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.14 |
| Last report | Jun 3, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +33.7% |
| Average move around a report | ±9.4% (last 5) |
| Sector | Healthcare · Biotechnology |
Spero Therapeutics earnings history: last 5 reports
Spero Therapeutics last reported on Jun 3, 2026: EPS of $0.91 against an estimate of $0.87 (+4.6% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Jun 3, 2026 | $0.87 | $0.91 | +4.6% | Beat | +5.3% |
| Nov 13, 2025 | -$0.25 | -$0.13 | +48.0% | Beat | -9.4% |
| Aug 12, 2025 | -$0.38 | -$0.03 | +92.1% | Beat | -12.1% |
| May 13, 2025 | -$0.44 | -$0.25 | +43.2% | Beat | +6.6% |
| Mar 27, 2025 | -$0.31 | -$0.37 | -19.4% | Miss | -13.8% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for SPRO
See the fair value, the probability range and the earnings history of Spero Therapeutics on its ATLAS page.
Spero Therapeutics (SPRO) stock analysisPlans from €3.99 a month.
Spero Therapeutics earnings: frequently asked questions
When does Spero Therapeutics (SPRO) report earnings?
Spero Therapeutics is scheduled to report on Thursday, November 12, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for SPRO?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.14 per share (USD). Estimates can change before the report.
How often does SPRO beat earnings estimates?
Of its last 5 reports with a recorded result, Spero Therapeutics beat the EPS estimate 4 times; the average surprise was +33.7%. Past results do not predict the next one.
How much does SPRO move around earnings?
Over its last 5 reports the stock moved an average of 9.4% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did Spero Therapeutics beat earnings estimates last quarter?
Spero Therapeutics last reported on Jun 3, 2026: EPS of $0.91 against an estimate of $0.87 (+4.6% surprise), a beat.
How much does SPRO usually move in a day?
On a normal trading day the ATLAS model puts SPRO’s one-day range at about ±3.9%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer